Late Stent Thrombosis (> 1 Year) Following Clopidogrel Withdrawal after Brachytherapy Treatment: Need to Assess Aspirin Resistance?

Catheterization and Cardiovascular Interventions

Volumn 62, Issue 1, 2004, Pages 39-42

  Jiménez Quevedo, Pilar ^a   Angiolillo, Dominick J ^a   Bernardo, Esther ^a   Sabaté, Manel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Aspirin resistance; Clopidogrel; Intracoronary brachytherapy; Late thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ANGIOCARDIOGRAPHY; BRACHYTHERAPY; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LATE STENT THROMBOSIS; MALE; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD VESSEL PROSTHESIS IMPLANTATION; BRACHYTHERAPY; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG RESISTANCE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE; TIME FACTORS;

EID: 2342524067     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10756     Document Type: Review

References (11)

1. Costa MA, Sabaté M, Van der Giessen WJ, Kay IP, Cervinka P, Ligthart JMR, Serrano P, Coen VLMA, Levendag PC, Serruys PW. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100:789-792.
2. Waksman R, Late thrombosis after radiation: sitting on a bomb. Circulation 1999;100:780-782.
3. Waksman R, Ajani AE, Pinnow E, Cheneau E, Leborgne L, Dieble R, Bui AB, Satler LF, Pichard AD, Kenneth K, Lidsay J. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing γ-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002;106;776-778.
4. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37-42.
5. Waksman R, Ajani AE, White LR, Pinnow E, Dieble R, Bui AB, Taaffe M, Gruberg L, Mintz GS, Satler LF, Pichard AD, Kenneth KK, Lidsay J. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary γ-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial Plus 6 Month of Clopidogrel (WRIST PLUS). Circulation 2001; 103:2332-2335.
6. Steinhubl SR, Berger PB, Mann JT III, Fry ET, De Lago A, Wilmer Topol EJ, CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420.
7. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan M, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI CURE study. Lancet 2001;358:527-533
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
9. Gum PA, Jottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirine resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
10. Kandzari DE, Goldschmidt-Clermont PJ. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. J Am Coll Cardiol 2001;38:1028-1032
11. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sánchez E, Broekman MJ, Marcus AJ. Erythrocyte promotion of platelet reactivity decrease the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350-355.